News

From our CEO

29 July 2025

Rohan Greenland The May 50K

In 2022, the Australian Government became a signatory to the global action plan on neurological disorders developed by the World Health Organisation (WHO).

Loud applause for that.

But the plan calls on WHO member nations to – among other things – develop national action plans to drive much-needed change.

Three years later, we still have no Australian action plan for neurological diseases, which affect an estimated seven million Australians, including more than 33,000 Australians living with multiple sclerosis.

Perhaps our applause was premature.

On September 4, the Neurological Alliance Australia – which I have the honour to chair – will launch a blueprint for an Australian action plan for neurological conditions. And we are doing so to prompt the Australian Government into action.

The blueprint has been in development since early this year, and I am grateful for the input from dozens of neurological and neuromuscular organisations, people living with neurological conditions and many others with expertise in neurological conditions.

By launching the blueprint, we hope to nudge the Australian Government – and also State and Territory governments – into action.

Yes, the WHO plan is a ten-year plan, running 2022-31. But we are over three years into the plan, and there is little evidence of any work to develop an Australian plan.

The blueprint will effectively be a guide for what we hope will be an Australian action plan, developed with the neurological community and backed by a robust, funded implementation plan.

It should be a ‘no-brainer’ for governments on economics alone.

There is robust evidence that shows that investment in prevention, treatment and rehabilitation could generate substantial savings over the course of the global plan.

So, mark September 4 in your diary and look out for our blueprint. It will be one big call for action.

Related News

MS News

National Pain Week: We need better answers for pain in multiple sclerosis

28 July 2026

CEO Rohan Greenland calls on the Australian Government to significantly boost support for pain and neurological research this National Pain Week, explaining why pain experienced by people living with MS is under-recognised and, too often, inadequately treated.

MS News

How does AHSCT compare with other MS treatments?

28 July 2026

New research shows AHSCT was superior to cladribine and alemtuzumab in reducing relapses in people with relapsing remitting MS.

MS News

Ocrevus and Kesimpta & the Government’s rapid review of MS medications

22 July 2026

On Thursday 16 July, the Australian Government announced that Ocrevus and Kesimpta would remain on the Pharmaceutical Benefits Scheme (PBS).

Read More

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

From our CEO